The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study
Carlo Visco(University of Verona), Ken H. Young(Duke Medical Center), Jane N. Winter(Northwestern University), Carlos E. Bueso‐Ramos(The University of Texas MD Anderson Cancer Center), Michael Møller(Hospital South West Jutland), Karen Dybkær(Aalborg University Hospital), Govind Bhagat(Columbia University Irving Medical Center), Maurilio Ponzoni(San Raffaele University of Rome), Eric D. Hsi(Mayo Clinic), Ronald S. Go(Mayo Clinic), Zijun Y. Xu‐Monette(Duke University), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Emanuele S. G. d'Amore(Ospedale San Bortolo), Attilio Orazi(Texas Tech University), Alexandar Tzankov(University of Basel), Magdalena Czader(Karolinska Institutet), Weiyun Z. Ai(City College of San Francisco), April Chiu(Mayo Clinic), Roberto N. Miranda(The University of Texas MD Anderson Cancer Center), Youli Zu(Methodist Hospital), Wayne Tam(Cornell University), Brad S. Kahl(UW Health University Hospital), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Santiago Montes‐Moreno(Universidad de Cantabria), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Huan‐You Wang(University of California San Diego), Frank Zhao(University of Maryland, Baltimore), Fan Zhou(Southwest Washington Medical Center), Xiaoying Zhao(Handan College), Joannes H.J.M. Van Krieken(Radboud University Nijmegen), William W.L. Choi(Chinese University of Hong Kong), L. Jeffrey Medeiros(Delaware Division of Libraries), Cherie H. Dunphy(Saint Louis University), Joan Etzell(University of California, San Francisco)
Cited by 5
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k